SpringerLink
Log in

Immunotherapy-Based Approaches for Treatment of Oral and Oropharyngeal Cancers

  • Chapter
  • First Online:
Textbook of Oral Cancer

Part of the book series: Textbooks in Contemporary Dentistry ((TECD))

  • 1495 Accesses

Abstract

Immunotherapy is emerging as an effective therapeutic option in a variety of cancers. The introduction of immune checkpoint inhibitors (ICI) in the management of head and neck cancer (HNSCC) documents the shift of a paradigm – treating the immune system rather than the tumor.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
USD 84.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. https://www.nice.org.uk/guidance/csg6/: improving outcomes in head and neck cancer, NICE June 2015.

  2. Lowe NM, Kershaw LE, Bernstein JM, Withey SB, Mais K, Homer JJ, Slevin NJ, Bonington SC, Carrington BM, West CM. Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy. PLoS One. 2018;13(3):e0194841.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.

    Article  PubMed  Google Scholar 

  4. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235–71.

    Article  PubMed  Google Scholar 

  5. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy--revisited. Nat Rev Drug Discov. 2011;10:591–600.

    Article  PubMed  Google Scholar 

  6. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer. 2007;120:781–7.

    Article  PubMed  Google Scholar 

  7. Sørensen RB, Hadrup SR, Svane IM, Hjortsø MC, Thor Straten P, Andersen MH. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood. 2011;117(7):2200–10.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12:269–81.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Humphries C. Adoptive cell therapy: honing that killer instinct. Nature. 2013;504:S13–5.

    Article  PubMed  Google Scholar 

  10. Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH. Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol. 2014;32:189.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. Nat Rev Clin Oncol. 2011;8:577–85.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, Klebanoff CA, Johnson LA, Kerkar SP, Yang S, Muranski P, Palmer DC, Scott CD, et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood. 2011;117:808–14.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Kershaw MH, Teng MW, Smyth MJ, Darcy PK. Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol. 2005;5:928–40.

    Article  PubMed  Google Scholar 

  14. Merhavi-Shoham E, Haga-Friedman A, Cohen CJ. Genetically modulating T-cell function to target cancer. Semin Cancer Biol. 2012;22:14–22.

    Article  PubMed  Google Scholar 

  15. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res. 2011;17:6287–97.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Pegram HJ, Jackson JT, Smyth MJ, Kershaw MH, Darcy PK. Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo. J Immunol. 2008;181:3449–55.

    Article  PubMed  Google Scholar 

  17. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30:658–70.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Foloppe J, Kintz J, Futin N, Findeli A, Cordier P, Schlesinger Y, Hoffmann C, Tosch C, Balloul JM, Erbs P. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther. 2008;15:1361–71.

    Article  PubMed  Google Scholar 

  19. Zhu W, Zhang H, Shi Y, Song M, Zhu B, Wei L. Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer. Cancer Biol Ther. 2013;14:1016–23.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Jiang G, Li J, Zeng Z, **an L. Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma. Cancer Biol Ther. 2006;5:435–40.

    Article  PubMed  Google Scholar 

  21. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64. https://doi.org/10.1038/nrc3239. Review.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342:1432–3.

    Article  PubMed  Google Scholar 

  23. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31:563–604.

    Article  PubMed  Google Scholar 

  24. Linette GP, Carreno BM. Dendritic cell-based vaccines: shining the spotlight on signal 3. Oncoimmunology. 2013;2:e26512.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Zentz C, Wiesner M, Man S, Frankenberger B, Wollenberg B, Hillemanns P, Zeidler R, Hammerschmidt W, Moosmann A. Activated B cells mediate efficient expansion of rare antigen-specific T cells. Hum Immunol. 2007;68(2):75–85.

    Article  PubMed  Google Scholar 

  26. Moosmann A, Khan N, Cobbold M, Zentz C, Delecluse HJ, Hollweck G, Hislop AD, Blake NW, Croom-Carter D, Wollenberg B, Moss PA, Zeidler R, Rickinson AB, Hammerschmidt W. B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. Blood. 2002;100(5):1755–64.

    Article  PubMed  Google Scholar 

  27. Wollenberg B, Kastenbauer MH, Schaumberg J, Mayer A, Andratschke M, Lang S, Pauli C, Zeidler R, Ihrler S, Löhrs NK, Rollston R. Gene therapy--phase I trial for primary untreated head and neck squamous cell cancer (HNSCC) UICC stage II-IV with a single intratumoral injection of hIL-2 plasmids formulated in DOTMA/Chol. Hum Gene Ther. 1999;10(1):141–7.

    Article  PubMed  Google Scholar 

  28. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol. 2011;30(1):16–34.

    Article  PubMed  Google Scholar 

  29. Pries R, Hogrefe L, **e L, Frenzel H, Brocks C, Ditz C, Wollenberg B. Induction of c-Myc-dependent cell proliferation through toll-like receptor 3 in head and neck cancer. Int J Mol Med. 2008;21(2):209–15.

    PubMed  Google Scholar 

  30. Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW. Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients with squamous cell carcinoma of the head and neck: the Active8 randomized clinical trial. JAMA Oncol. 2018;4(11):1583–8.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Immunity. 2013;39(1):1–10.

    Article  PubMed  Google Scholar 

  32. Palucka AK, Coussens LM. The basis of oncoimmunology. Cell. 2016;164(6):1233–47.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. Clinical significance of PD-L1+ exosomes in plasma of head and neck cancer patients. Clin Cancer Res. 2018;24(4):896–905. Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology. 2013; 2:e24612.

    Article  PubMed  Google Scholar 

  34. Rolfes V, Idel C, Pries R, Plötze-Martin K, Habermann J, Gemoll T, Bohnet S, Latz E, Ribbat-Idel J, Franklin BS, Wollenberg B. PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy. Oncotarget. 2018;9(44):27460–70.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018;81:45–51.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ. KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomized, open-label, phase 3 study. Lancet. 2018. pii: S0140-6736(18)31999-8.

    Google Scholar 

  37. Harrington KJ, Ferris RL, Blumenschein G Jr, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grünwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (Check Mate 141): health-related quality-of-life results from a randomized, phase 3 trial. Lancet Oncol. 2017;18(8):1104–15.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Wollenberg B. PD-1 antibodies in head-and-neck cancer. Lancet. 2018. pii: S0140-6736(18)32346-8.

    Google Scholar 

  39. Burtness B. ESMO 2018.

    Google Scholar 

  40. Hryniewicki AT, Wang C, Shatsky RA, Coyne CJ. Management of Immune Checkpoint Inhibitor Toxicities: a review and clinical guideline for emergency physicians. J Emerg Med. 2018;55(4):489–502.

    Article  PubMed  Google Scholar 

  41. Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447–58.

    Article  PubMed  Google Scholar 

  42. Cristescu R, Kaufman D. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362(6411). pii: eaar3593. https://doi.org/10.1126/science.aar3593.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–608.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science. 2018;359(6382):1366–70.

    Article  PubMed  Google Scholar 

  45. Blank CU, Haanen JB, Ribas A, Schumacher TN. CANCER IMMUNOLOGY. The “cancer immunogram”. Science. 2016;352(6286):658–60.

    Article  PubMed  Google Scholar 

  46. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011;11:805–12.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015;41(6):503–10.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic for Otorhinolaryngology, Head and Neck Surgery, MRI Klinikum rechts der Isar der Technischen Universität München, Munich, Germany

    Barbara Wollenberg

Authors
  1. Barbara Wollenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barbara Wollenberg .

Editor information

Editors and Affiliations

  1. Faculty of Dentistry, Oral & Craniofacial Sciences,, King’s College London, London, UK

    Saman Warnakulasuriya

  2. Department of Orofacial Sciences, Schools of Dentistry and Medicine, University of California San Francisco, San Francisco, CA, USA

    John S. Greenspan

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wollenberg, B. (2020). Immunotherapy-Based Approaches for Treatment of Oral and Oropharyngeal Cancers. In: Warnakulasuriya, S., Greenspan, J. (eds) Textbook of Oral Cancer. Textbooks in Contemporary Dentistry. Springer, Cham. https://doi.org/10.1007/978-3-030-32316-5_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-32316-5_28

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-32315-8

  • Online ISBN: 978-3-030-32316-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation